|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15361537153815391540154115421543154415451546...15771578» |
- || Trial primary completion date: Assessing the Patient Experience in Cancer Care (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=760, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2015 --> Dec 2015
- Trial primary completion date: Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=15, Recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
Trial primary completion date: May 2015 --> Dec 2015 Trial primary completion date: May 2015 --> Aug 2020
- | Ogsiveo (nirogacestat) / SpringWorks Therap
Trial initiation date, Trial primary completion date: Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=20, Not yet recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
Trial primary completion date: May 2015 --> Aug 2020 Initiation date: Jun 2014 --> Jul 2015 | Trial primary completion date: Aug 2015 --> Jul 2017
- Enrollment change: Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=40, Recruiting, Sponsor: Stanford University
Initiation date: Jun 2014 --> Jul 2015 | Trial primary completion date: Aug 2015 --> Jul 2017 N=20 --> 40
- retaspimycin (IPI-504) / Infinity Pharma
Enrollment change, Metastases: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=0, Withdrawn, Sponsor: Infinity Pharmaceuticals, Inc.
N=20 --> 40 N=40 --> 0
- New trial, MRI: Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy (clinicaltrials.gov) - Apr 14, 2015
P2, N=56, Recruiting, Sponsor: Washington University School of Medicine
N=40 --> 0 Not yet recruiting --> Recruiting
- Stivarga (regorafenib) / Bayer
Enrollment change, Stroma, Metastases: WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib (clinicaltrials.gov) - Apr 10, 2015
P=N/A, N=5, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting --> Recruiting N=30 --> 5
- || imatinib / Generic mfg.
New P3 trial, New P4 trial: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST (clinicaltrials.gov) - Apr 10, 2015
P3, N=300, Not yet recruiting, Sponsor: Heikki Joensuu
- |||| Sutent (sunitinib) / Pfizer
Trial completion: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene (clinicaltrials.gov) - Apr 9, 2015
P4, N=620, Completed, Sponsor: Pfizer
N=30 --> 5 Enrolling by invitation --> Completed
- Farydak (panobinostat) / Secura Bio
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers (clinicaltrials.gov) - Apr 8, 2015
P1, N=50, Active, not recruiting, Sponsor: Medical University of South Carolina
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Mar 2014
- cyclophosphamide / Generic mfg.
New P1/2 trial, New P2 trial: NKEXPSARC: Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas (clinicaltrials.gov) - Apr 7, 2015
P1/2, N=20, Recruiting, Sponsor: National University Hospital, Singapore
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, PD(L)-1 Biomarker, Surgery, Metastases: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 6, 2015
P1, N=42, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Apr 6, 2015
P1/2, N=204, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Mar 2014 Suspended --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Apr 6, 2015
P1, N=216, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Recruiting --> Active, not recruiting
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. (clinicaltrials.gov) - Apr 6, 2015
P2, N=96, Active, not recruiting, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016
- |||| sunitinib / Generic mfg.
Trial completion, Metastases: Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Apr 4, 2015
P2, N=72, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016 Active, not recruiting --> Completed
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
New P1 trial, Metastases: BGB-A317_Study_001: Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors (clinicaltrials.gov) - Apr 3, 2015
P1, N=64, Not yet recruiting, Sponsor: BeiGene
- Lartruvo (olaratumab) / Eli Lilly
Enrollment open, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Apr 3, 2015
P1, N=18, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: 18F-FES PET/CT in Imaging Patients With Desmoid Tumors (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=10, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma (clinicaltrials.gov) - Apr 3, 2015
P2, N=49, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Metastases: PEMBROSARC: Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (clinicaltrials.gov) - Apr 2, 2015
P2, N=163, Not yet recruiting, Sponsor: Institut Bergoni
- ||||| bezuclastinib (PLX9486) / Cogent Biosci
Combination therapy, Stroma, Metastases: CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=92, Recruiting, Sponsor: Plexxikon
- | Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Enrollment change: PASART-1: Combined Modality Treatment of Sarcomas of the Extremities (clinicaltrials.gov) - Mar 31, 2015
P1, N=12, Completed, Sponsor: The Netherlands Cancer Institute
Suspended --> Active, not recruiting Recruiting --> Completed | N=15 --> 12
- | Leukine (sargramostim) / Partner Therap
Trial completion: COG-AOST0221: Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma (clinicaltrials.gov) - Mar 31, 2015
P2, N=49, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | N=15 --> 12 Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open, Trial initiation date, Trial primary completion date: Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer (clinicaltrials.gov) - Mar 26, 2015
P3, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Aug 2013 | Trial primary completion date: Jan 2015 --> Sep 2017
- | gemcitabine / Generic mfg.
Trial completion, Trial initiation date: PP-Gemcitabine & External Beam Radiation-Sarcomas (clinicaltrials.gov) - Mar 26, 2015
P1, N=41, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Aug 2013 | Trial primary completion date: Jan 2015 --> Sep 2017 Active, not recruiting --> Completed | Initiation date: Dec 2007 --> Dec 2001
- Trial completion, Trial primary completion date: Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core) (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=76, Completed, Sponsor: Indiana University
Active, not recruiting --> Completed | Initiation date: Dec 2007 --> Dec 2001 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014
- |||| Odomzo (sonidegib) / Sun Pharma
Trial completion, Trial primary completion date: A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB (clinicaltrials.gov) - Mar 26, 2015
P1/2, N=76, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014 Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Oct 2014
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, PARP Biomarker, Metastases: Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) (clinicaltrials.gov) - Mar 25, 2015
P1, N=40, Recruiting, Sponsor: Italian Sarcoma Group
- |||| Kisqali (ribociclib) / Novartis, siremadlin (HDM201) / Novartis
Enrollment open, Combination therapy: Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma (clinicaltrials.gov) - Mar 23, 2015
P1/2, N=86, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Oct 2014 Not yet recruiting --> Recruiting
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Enrollment change, Tumor cell: Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - Mar 23, 2015
P1, N=10, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Completed | N=25 --> 10
- Review, Enrollment change: Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 20, 2015
P=N/A, N=1, Terminated, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Completed | N=25 --> 10 N=20 --> 1
- |||| MV-NIS / Vyriad
Enrollment open: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer (clinicaltrials.gov) - Mar 20, 2015
P2, N=134, Recruiting, Sponsor: Mayo Clinic
N=20 --> 1 Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine (clinicaltrials.gov) - Mar 20, 2015
P2, N=94, Recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment change, Surgery: Radiosurgery Plus Bevacizumab in Glioblastoma (clinicaltrials.gov) - Mar 19, 2015
P1/2, N=9, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting N=74 --> 9
- || Enrollment change: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies (clinicaltrials.gov) - Mar 19, 2015
P=N/A, N=7500, Recruiting, Sponsor: Children's Oncology Group
N=74 --> 9 N=906 --> 7500
- New P1 trial, Combination therapy: AflacST1402: Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (clinicaltrials.gov) - Mar 19, 2015
P1, N=36, Recruiting, Sponsor: Emory University
- Keytruda (pembrolizumab) / Merck (MSD), Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, PD(L)-1 Biomarker, Metastases: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - Mar 19, 2015
P1, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
N=906 --> 7500 Not yet recruiting --> Recruiting
- digoxin / Generic mfg.
Enrollment open: KADIG 01: Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma (clinicaltrials.gov) - Mar 18, 2015
P2, N=17, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Turalio (pexidartinib) / Daiichi Sankyo
New P1/2 trial: Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... (clinicaltrials.gov) - Mar 18, 2015
P1/2, N=45, Recruiting, Sponsor: National Cancer Institute (NCI)
- trebananib (AMG 386) / Amgen
Enrollment closed, Surgery, Metastases: Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 17, 2015
P2, N=16, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- Enrollment change: Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer (clinicaltrials.gov) - Mar 17, 2015
P2, N=131, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Suspended --> Active, not recruiting N=77 --> 131
- | thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus (clinicaltrials.gov) - Mar 15, 2015
P2, N=60, Completed, Sponsor: National Cancer Institute (NCI)
N=77 --> 131 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, rilotumumab (AMG 102) / Amgen
Trial primary completion date: AMG 102 and Avastin for Recurrent Malignant Glioma (clinicaltrials.gov) - Mar 14, 2015
P2, N=36, Active, not recruiting, Sponsor: Katy Peters
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Nov 2014
- hydroxyurea / Generic mfg.
Enrollment change: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors (clinicaltrials.gov) - Mar 12, 2015
P2, N=0, Withdrawn, Sponsor: Children's Hospital of Philadelphia
Trial primary completion date: Feb 2015 --> Nov 2014 N=10 --> 0
- ||| Tabrecta (capmatinib) / Incyte, Novartis, Avastin (bevacizumab) / Roche
New P1 trial, Combination therapy: INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Mar 12, 2015
P1, N=63, Not yet recruiting, Sponsor: SCRI Development Innovations, LLC
- | CMB305 / Merck (MSD)
New P1 trial, Metastases: Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Mar 12, 2015
P1, N=33, Recruiting, Sponsor: Immune Design
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas (clinicaltrials.gov) - Mar 12, 2015
P2, N=80, Recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=10 --> 0 Not yet recruiting --> Recruiting
- adavosertib (AZD1775) / AstraZeneca
Trial primary completion date, Combination therapy: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 11, 2015
P1/2, N=128, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Oct 2017